Jaguar Health establishes first study site for Canalevia-CA1 field study

Jaguar Health (JAGX) announced that the first study site has been established for Jaguar’s field study of Canalevia-CA1, Jaguar’s U.S. Food and Drug Administration conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea in dogs. Jaguar has two parallel goals for Canalevia-CA1: To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea in dogs and to expand the indication of crofelemer from CID in dogs to treatment of general, non-infectious diarrhea in dogs. The company is in discussions with potential partners to fund development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally. The objective of the prospective, randomized, open-label field study in dogs undergoing chemotherapy treatment across the U.S. is to collect real-world data to demonstrate real-world evidence of the clinical effectiveness for Canalevia-CA1 for the treatment of CID in dogs to support potential full FDA approval of the drug for this indication. Dogs enrolled in this study will be randomly assigned to receive a prescription of Canalevia-CA1 as a treatment for CID or be randomly selected to the control group.